Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 388 of the 388 references it cites were found in a registry or an index.

The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives

Open access
Wang, Shun, Zheng, Yan, Yang, Feng, Zhu, Le, Zhu, Xiao-Qiang, Wang, Zhe-Fang, Wu, Xiao-Lin, Zhou, Cheng-Hui, Yan, Jia-Yan, Hu, Bei-Yuan, Kong, Bo, Fu, De-Liang, Bruns, Christiane, Zhao, Yue, Qin, Lun-Xiu, Dong, Qiong-Zhu·2021·Signal Transduction and Targeted Therapy

Abstract

Pancreatic cancer is an increasingly common cause of cancer mortality with a tight correspondence between disease mortality and incidence. Furthermore, it is usually diagnosed at an advanced stage with a very dismal prognosis. Due to the high heterogeneity, metabolic reprogramming, and dense stromal environment associated with pancreatic cancer, patients benefit little from current conventional therapy. Recent insight into the biology and genetics of pancreatic cancer has supported its molecular classification, thus expanding clinical therapeutic options. In this review, we summarize how the biological features of pancreatic cancer and its metabolic reprogramming as well as the tumor microenvironment regulate its development and progression. We further discuss potential biomarkers for pancreatic cancer diagnosis, prediction, and surveillance based on novel liquid biopsies. We also outline recent advances in defining pancreatic cancer subtypes and subtype-specific therapeutic responses and current preclinical therapeutic models. Finally, we discuss prospects and challenges in the clinical development of pancreatic cancer therapeutics.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41392-021-00659-4

Cites

388 of 388 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 The characteristics of pancreatic adenocarcinoma. Pancreatic cancer is a common cause of cancer mortality characterized by high heterogeneity, a dense stromal tumor microenvironment (TME), highly metastatic propensity, metabolic reprogramming, and limited benefits from current conventional therapies. a Genetic and epigenetic changes in pancreatic cancer. KRAS (~90%), TP53 (50–74%), CDKN2A (46–60%), and SMAD4 (31–38%) are the most frequently mutated genes known to modulate the initiation and progression of pancreatic cancer. Epigenetic regulatory genes, including MLL2/3, KDM6A, and multiple HDACs encoding genes, regulate histone modification. SMARCA2/4 and ARID2 modulate chromatin remodeling. b Therapeutic limitations in pancreatic cancer. Surgical resection is the only potentially curative choice for pancreatic cancer patients. Adjuvant chemotherapy can only partially improve the overall survival of pancreatic cancer patients c Pancreatic cancer is an extremely aggressive tumor with high metastatic propensity. The immunosuppressive TME plays an important role in modulating the metastasis of pancreatic cancer cells to the liver, lungs, peritoneum, and bone. d Metabolic reprogramming of pancreatic cancer. Pancreatic cancer cells can survive and proliferate in stressful microenvironments by reprogramming energy metabolism to increase glucose and glutamine uptake, macropinocytosis, and autophagy
Fig. 1 The characteristics of pancreatic adenocarcinoma. Pancreatic cancer is a common cause of cancer mortality characterized by high heterogeneity, a dense stromal tumor microenvironment (TME), highly metastatic propensity, metabolic reprogramming, and limited benefits from current conventional therapies. a Genetic and epigenetic changes in pancreatic cancer. KRAS (~90%), TP53 (50–74%), CDKN2A (46–60%), and SMAD4 (31–38%) are the most frequently mutated genes known to modulate the initiation and progression of pancreatic cancer. Epigenetic regulatory genes, including MLL2/3, KDM6A, and multiple HDACs encoding genes, regulate histone modification. SMARCA2/4 and ARID2 modulate chromatin remodeling. b Therapeutic limitations in pancreatic cancer. Surgical resection is the only potentially curative choice for pancreatic cancer patients. Adjuvant chemotherapy can only partially improve the overall survival of pancreatic cancer patients c Pancreatic cancer is an extremely aggressive tumor with high metastatic propensity. The immunosuppressive TME plays an important role in modulating the metastasis of pancreatic cancer cells to the liver, lungs, peritoneum, and bone. d Metabolic reprogramming of pancreatic cancer. Pancreatic cancer cells can survive and proliferate in stressful microenvironments by reprogramming energy metabolism to increase glucose and glutamine uptake, macropinocytosis, and autophagyCC BY · PubMed Central
Fig. 2 Metabolic reprogramming in pancreatic cancer cells. KRAS activation and mutant TP53 enhance glucose metabolism to provide biosynthetic precursors for anabolic pathways, including the non-oxidative arm of the pentose phosphate pathway (PPP) and the hexosamine biosynthesis pathway (HBP). KRAS activation reprograms glutamine metabolism to sustain cellular redox homeostasis by increasing the NADPH/NADP+ ratio and recycling glutathione (GSH) via reduction of oxidized GSH. The BCAT2-mediated BCAA catabolism driven by KRAS plays a critical role during pancreatic cancer development. Enhanced nutrient salvaging, via the induction of macropinocytosis and autophagy, provides energy and regenerative nutrients, including glucose, amino acids, lipids, and nucleosides
Fig. 2 Metabolic reprogramming in pancreatic cancer cells. KRAS activation and mutant TP53 enhance glucose metabolism to provide biosynthetic precursors for anabolic pathways, including the non-oxidative arm of the pentose phosphate pathway (PPP) and the hexosamine biosynthesis pathway (HBP). KRAS activation reprograms glutamine metabolism to sustain cellular redox homeostasis by increasing the NADPH/NADP+ ratio and recycling glutathione (GSH) via reduction of oxidized GSH. The BCAT2-mediated BCAA catabolism driven by KRAS plays a critical role during pancreatic cancer development. Enhanced nutrient salvaging, via the induction of macropinocytosis and autophagy, provides energy and regenerative nutrients, including glucose, amino acids, lipids, and nucleosidesCC BY · PubMed Central
Fig. 3 Immune evasion orchestrated by pancreatic cancer cells and stromal cells. The secretion and immunomodulation of pro-tumorigenic cytokines by pancreatic cancer cells and stromal cells are tightly regulated by oncogenic KRAS- or mutant TP53-dependent pathways. Pancreatic cancer cells secrete cytokines and, chemokines and recruit immunosuppressive cells, including MDSCs, TAMs, Treg cells, and neutrophils, which suppress the activity and functions of CD8+ cytotoxic T cells. Pancreatic cancer cells also evade the immune system by expressing PDL-1 to promote CD8+ T cell exhaustion. Immune cell infiltration also releases cytokines and growth factors that directly stimulate tumor growth by promoting angiogenesis and increasing the invasive ability of pancreatic cancer cells
Fig. 3 Immune evasion orchestrated by pancreatic cancer cells and stromal cells. The secretion and immunomodulation of pro-tumorigenic cytokines by pancreatic cancer cells and stromal cells are tightly regulated by oncogenic KRAS- or mutant TP53-dependent pathways. Pancreatic cancer cells secrete cytokines and, chemokines and recruit immunosuppressive cells, including MDSCs, TAMs, Treg cells, and neutrophils, which suppress the activity and functions of CD8+ cytotoxic T cells. Pancreatic cancer cells also evade the immune system by expressing PDL-1 to promote CD8+ T cell exhaustion. Immune cell infiltration also releases cytokines and growth factors that directly stimulate tumor growth by promoting angiogenesis and increasing the invasive ability of pancreatic cancer cellsCC BY · PubMed Central
Fig. 4 Current clinical strategies in pancreatic cancer. For patients with pancreatic cancer, the primary clinical strategies rely on chemotherapy, whereas novel therapeutic agents targeting DNA repair, gene mutations, tumor metabolism, tumor microenvironments, or immune checkpoints might improve their prognosis. Currently, increasing interest has emerged in combined chemotherapy and immunotherapy or targeted therapy
Fig. 4 Current clinical strategies in pancreatic cancer. For patients with pancreatic cancer, the primary clinical strategies rely on chemotherapy, whereas novel therapeutic agents targeting DNA repair, gene mutations, tumor metabolism, tumor microenvironments, or immune checkpoints might improve their prognosis. Currently, increasing interest has emerged in combined chemotherapy and immunotherapy or targeted therapyCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 388 references

Cited by

See all 370

Metadata

Authors
Wang, S., Zheng, Y., Yang, F., Zhu, L., Zhu, X.-Q., Wang, Z.-F., Wu, X.-L., Zhou, C.-H., Yan, J.-Y., Hu, B.-Y., Kong, B., Fu, D.-L., Bruns, C., Zhao, Y., Qin, L.-X., & Dong, Q.-Z.
Affiliations
  • Fudan University (CN)
  • University Hospital Cologne (DE)
  • TUM Klinikum (DE)
Corresponding author
  • Zhao, Yue
  • Qin, Lun-Xiu
Venue
Signal Transduction and Targeted Therapy
Published
2021-07-05
Volume
6
Issue
1
Pages
249-249
ISSN
2059-3635 (ISSN-L)
OpenAlex
W3179240236
Cited by
369
References
388
Citations by year
2026: 62 · 2025: 91 · 2024: 92 · 2023: 70 · 2022: 50 · 2021: 4
FWCI
6.57
Type
journal article
Language
en
Open access
Licence
Locations
  • Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (81672820, 20XD1400900, 81940074, 81872356, 81802903)
  • Shanghai International Science and Technology
  • National Key Research and Development Program of China (2017YFC1308604)
  • Program of Shanghai Academic Research Leader (20XD1400900)
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords
pancreatic ductal adenocarcinoma, metabolic reprogramming, tumor microenvironment, molecular classification, biomarkers, liquid biopsy, cancer therapeutics, tumor heterogeneity
MeSH terms
Adenocarcinoma, Humans, Pancreatic Neoplasms, Prognosis, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives. https://app.cochat.ai/papers/10.1038/s41392-021-00659-4
The paper
Wang, S., Zheng, Y., Yang, F., Zhu, L., Zhu, X.-Q., Wang, Z.-F., Wu, X.-L., Zhou, C.-H., Yan, J.-Y., Hu, B.-Y., Kong, B., Fu, D.-L., Bruns, C., Zhao, Y., Qin, L.-X., & Dong, Q.-Z. (2021). The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-021-00659-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.